X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

MRKR

Closed

Marker Therapeutics Inc

1.51
-0.02 (-1.31%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.53
Day's Range: 1.4801 - 1.55
Send
When Written:
 
0.85
Marker Therapeutics Inc. is a clinical-stage immuno-oncology company that develops novel T cell-based immunotherapies for the treatment of various cancers. The company's proprietary MultiTAA technology platform allows for the creation of personalized T cell therapies that target multiple tumor-associated antigens (TAAs) simultaneously, increasing the effectiveness of the therapy. Marker Therapeutics' lead product candidate, MT-401, is a potential treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing other T cell therapies targeting solid tumors such as breast cancer and lung cancer. Marker Therapeutics is headquartered in Houston, Texas, and was founded in 2014.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X